Filed Under:  U.S. & World

Investors Sell Shares of Bristol-Myers Squibb on Strength (BMY)

Contributed by on November 24, 2015 at 11:48 am

Pharmaceutical company Bristol-Myers Squibb Company (BMY) announced that the European Commission has approved the reconciliation of indications for nivolumab under the Opdivo European Marketing Authorization Application (MAA). The firm has a market capitalization of $111.68 billion and a PE ratio of 63.03. Leerink Swann reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 28th. The shares were sold at an average price of $59.40, for a total value of $1,378,080.00.



Immuno-oncology has been one of the most dynamic areas in biotechnology for a few years, and Bristol-Myers Squibb is widely acknowledged to be one of the leaders in this innovative field.

What are the estimates Bristol Myers Squibb Company’s earnings? We are excited to be working with Bristol-Myers Squibb and welcome Dr.

Bristol-Myers Squibb Firm (NYSE:BMY) [Trend Analysis] hits high price of $67.88 to close at $66.94 by moving down -0.99% in last trading session with share volume of 4.01 Million that was surprisingly higher than its average volume of 7498.75 shares.

Bristol-Myers Squibb Co (NYSE:BMY) has risen 2.09% since April 22, 2015 and is uptrending. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.04. The reported GAAP net loss for the quarter primarily reflects an increase in costs related to strategic transactions including upfront collaboration expenses driven by the Juno Therapeutics collaboration, inclusive of the premium paid to acquire an equity stake, as well as expenses incurred in connection with the acquisition of Receptos. It operates in BioPharmaceuticals. The Business ‘s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. Institutional Investors own 72.14% of Bristol-Myers Squibb Company shares. The OS benefit was observed across patient subgroups, with the greatest improvement with nivolumab seen for those with a poor MSKCC prognostic score (HR, 0.47; 95% CI, 0.30-0.73). Counter to that, the lowest was $0.47. During the same quarter in the previous year, the firm posted $0.45 earnings per share. It is the seventh drug approved by the FDA for the treatment of patients with melanoma. Also, because of different datasources, our reporting and figures may be different then the numbers reported by FactSet and other sources. This is not a cause for alarm, please do not contact us about this.

The overall rating for the company is 1.81. Finally, Berenberg Bank lifted their price objective on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the company a “hold” rating in a research report on Monday, November 2nd. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares, and Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares…. Among the 6 analysts who were surveyed, the consensus expectation for quarterly sales had been 3845.775M. Similar drugs include Yervoy, also from Bristol-Myers and Merck’s Keytruda.

Investors Sell Shares of Bristol-Myers Squibb on Strength (BMY)